TTOO - T2 Biosystems Inc Stock Price, Fair Value and News

5.67USD+0.03 (+0.53%)Market Closed

Market Summary

USD5.67+0.03

Market Closed

0.53%

TTOO Stock Price

View Fullscreen

TTOO RSI Chart

TTOO Valuation

Market Cap

49.9M

Price/Earnings (Trailing)

-1.09

Price/Sales (Trailing)

6.95

Price/Free Cashflow

-1.06

TTOO Price/Sales (Trailing)

TTOO Profitability

Return on Equity

120.76%

Return on Assets

-184.39%

Free Cashflow Yield

-94.41%

TTOO Fundamentals

TTOO Revenue

Revenue (TTM)

7.2M

Rev. Growth (Yr)

-0.82%

Rev. Growth (Qtr)

22.75%

TTOO Earnings

Earnings (TTM)

-45.6M

Earnings Growth (Yr)

24.66%

Earnings Growth (Qtr)

-30.89%

Breaking Down TTOO Revenue

Last 7 days

53.7%

Last 30 days

92.9%

Last 90 days

4.0%

Trailing 12 Months

1967.8%

How does TTOO drawdown profile look like?

TTOO Financial Health

Current Ratio

0.28

TTOO Investor Care

Shares Dilution (1Y)

4216.94%

Diluted EPS (TTM)

49.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	7.2M	0	0	0
2023	17.1M	13.2M	11.0M	7.2M
2022	28.3M	27.6M	23.8M	22.3M
2021	22.5M	26.7M	28.9M	28.1M
2020	9.1M	9.8M	13.4M	18.1M
2019	10.0M	7.8M	7.1M	8.3M
2018	6.0M	9.0M	10.4M	10.5M
2017	3.9M	3.9M	3.9M	4.7M
2016	3.7M	4.1M	4.2M	4.1M
2015	454.0K	927.0K	1.9M	2.8M
2014	0	0	0	385.0K
2013	0	101.3K	183.7K	266.0K
2012	0	0	0	19.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of T2 Biosystems Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	cr group l.p.	acquired	-	-	403,608	-
May 03, 2024	cr group l.p.	acquired	-	-	1,565,440	-
May 03, 2024	cr group l.p.	acquired	-	-	129,629	-
May 03, 2024	cr group l.p.	acquired	-	-	2,001,510	-
May 03, 2024	cr group l.p.	acquired	-	-	648,139	-
Apr 12, 2024	cr group l.p.	acquired	-	-	682,036	-
Apr 12, 2024	cr group l.p.	acquired	-	-	424,716	-
Apr 12, 2024	cr group l.p.	acquired	-	-	390,142	-
Apr 12, 2024	cr group l.p.	acquired	-	-	1,647,320	-
Apr 12, 2024	cr group l.p.	acquired	-	-	136,409	-

Which funds bought or sold TTOO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-96,741	-	-%
May 15, 2024	MORGAN STANLEY	reduced	-88.33	-711	42.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-7.00	6.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	40.17	-4,221	8,574	-%
May 15, 2024	Royal Bank of Canada	added	6.3	-4,000	4,000	-%
May 13, 2024	UBS Group AG	new	-	5,250	5,250	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	15.74	-67,435	83,538	-%
May 10, 2024	GROUP ONE TRADING, L.P.	reduced	-37.7	-14,469	6,138	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	-149,651	137,085	-%
May 10, 2024	BlackRock Inc.	unchanged	-	-121,047	110,883	-%

Are Funds Buying or Selling TTOO?

Are funds buying TTOO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TTOO

No. of Funds

Unveiling T2 Biosystems Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	cr group l.p.	69.5%	10,677,973	SC 13D/A
May 07, 2024	cr group l.p.	65.4%	8,853,173	SC 13D/A
Apr 19, 2024	cr group l.p.	46.68%	4,104,838	SC 13D
Mar 11, 2024	safier jacob	7.1%	350,000	SC 13G
Mar 11, 2024	new dimensions trading	7.1%	350,000	SC 13G
Feb 13, 2024	lind global fund ii lp	0.5%	20,370	SC 13G/A
Jul 31, 2023	gsa capital partners llp	1.5%	4,599,059	SC 13G
Jul 13, 2023	cr group l.p.	19.9%	72,503,592	SC 13G
Jun 30, 2023	gsa capital partners llp	15.2%	3,799,487	SC 13G
Jun 23, 2023	carrick jason	8%	2e+06	SC 13G

Recent SEC filings of T2 Biosystems Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	RW	RW
May 13, 2024	4	Insider Trading
May 13, 2024	SC 13D/A	13D - Major Acquisition
May 08, 2024	FWP	Prospectus Filed
May 07, 2024	SC 13D/A	13D - Major Acquisition
May 07, 2024	FWP	Prospectus Filed
May 07, 2024	FWP	Prospectus Filed
May 07, 2024	8-K	Current Report
May 07, 2024	4	Insider Trading

Peers (Alternatives to T2 Biosystems Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

T2 Biosystems Inc News

Latest updates

T2 Biosystems Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	22.8%	2,061	1,679	1,472	1,964	2,078	5,483	3,677	5,911	7,234	6,980	7,428	6,694	6,956	7,788	5,245	2,552	2,545	3,069	1,677	1,804	1,785
Costs and Expenses	33.3%	14,661	10,998	15,079	15,015	15,765	15,003	19,477	20,930	22,091	17,259	19,640	17,474	16,658	16,108	15,881	11,391	16,106	15,436	14,023	15,590	15,344
S&GA Expenses	28.2%	6,738	5,255	5,980	6,296	7,299	6,554	7,017	7,824	9,230	6,544	8,536	7,244	6,203	4,868	5,266	5,305	6,655	7,546	5,981	6,722	7,055
R&D Expenses	17.4%	3,721	3,169	2,663	3,850	4,471	4,659	6,375	8,025	6,656	5,353	6,384	5,399	4,665	3,764	3,782	3,786	4,780	4,279	4,098	4,048	3,901
Interest Expenses	360.6%	839	-322	1,119	1,541	1,522	-639	1,560	1,346	1,650	2,369	1,919	1,881	1,013	1,610	647	1,844	1,417	3,914	1,168	1,136	1,131
Net Income	-30.9%	-13,534	-10,340	-15,425	-6,347	-17,965	-10,099	-17,375	-18,034	-16,495	-12,144	-13,962	-12,475	-10,660	-9,909	-11,255	-10,685	-14,949	-14,041	-14,171	-15,647	-15,147
Net Income Margin	8.6%	-6.36*	-6.96*	-4.53*	-3.92*	-3.70*	-2.78*	-2.69*	-2.20*	-1.94*	-1.75*	-1.63*	-1.66*	-1.89*	-2.58*	-	-	-	-	-	-	-
Free Cashflow	-24.0%	-11,709	-9,442	-13,406	-12,420	-13,060	-10,365	-16,029	-10,104	-14,470	-10,041	-9,685	-10,703	-8,905	-9,129	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-28.9%	25.00	35.00	43.00	37.00	33.00	34.00	44.00	40.00	49.00	61.00	70.00	79.00	70.00	79.00	78.00	54.00	51.00	28.00	34.00	45.00	56.00
Current Assets	-38.2%	16.00	25.00	33.00	24.00	19.00	19.00	29.00	25.00	34.00	44.00	54.00	64.00	45.00	54.00	51.00	47.00	44.00	19.00	24.00	33.00	44.00
Cash Equivalents	-56.7%	7.00	16.00	24.00	16.00	10.00	10.00	20.00	13.00	9.00	22.00	22.00	33.00	11.00	17.00	19.00	27.00	36.00	11.00	16.00	28.00	37.00
Inventory	-3.1%	5.00	5.00	4.00	4.00	5.00	4.00	4.00	6.00	5.00	4.00	5.00	5.00	5.00	4.00	4.00	4.00	3.00	4.00	4.00	3.00	3.00
Net PPE	-2.8%	2.00	2.00	2.00	5.00	5.00	5.00	5.00	4.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	6.00	6.00	7.00	7.00
Liabilities	-0.5%	63.00	63.00	63.00	74.00	83.00	74.00	-	-	-	73.00	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	0.2%	56.00	56.00	55.00	66.00	18.00	10.00	11.00	13.00	13.00	12.00	11.00	9.00	10.00	10.00	10.00	8.00	58.00	61.00	58.00	58.00	54.00
Shareholder's Equity	-34.8%	-37.80	-28.04	-	-	-49.89	-39.65	-	-	-	-12.90	-	9.00	-	9.00	18.00	-	-	-	-	-	-
Retained Earnings	-2.3%	-597	-584	-574	-558	-552	-534	-524	-506	-488	-472	-460	-446	-433	-422	-413	-401	-391	-376	-362	-347	-332
Additional Paid-In Capital	0.7%	560	556	555	522	502	495	492	469	463	459	457	455	433	432	431	397	383	342	336	332	331
Shares Outstanding	35.8%	6.00	4.00	4.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-
Float	-	-	-	-	17.00	-	-	-	31.00	-	-	-	189	-	-	-	148	-	-	-	64.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-24.1%	-11,683	-9,416	-13,393	-12,387	-12,940	-10,329	-15,903	-9,956	-14,441	-9,842	-9,727	-10,597	-8,708	-8,750	-6,234	-13,491	-14,740	-10,119	-13,535	-8,840	-12,867
Share Based Compensation	119.1%	1,595	728	877	913	1,833	1,035	1,372	1,534	2,552	1,473	2,466	1,843	1,308	904	855	994	1,160	983	1,165	1,277	2,033
Cashflow From Investing	100.0%	-	-26.00	-13.00	-33.00	-120	-36.00	-126	9,850	-29.00	9,801	42.00	12,395	2,553	6,372	-33,263	-9,303	-67.00	-26.00	-291	-250	-194
Cashflow From Financing	171.2%	2,202	812	21,641	18,387	11,848	748	23,183	3,921	1,202	239	24.00	20,219	53.00	112	32,398	13,000	40,097	4,965	1,617	112	-344

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TTOO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 2,061	$ 2,078
Costs and expenses:
Research and development	3,721	4,471
Selling, general and administrative	6,738	7,299
Total costs and expenses	14,661	15,765
Loss from operations	(12,600)	(13,687)
Other income (expense):
Interest expense to related party	(1,179)	(1,522)
Change in fair value of derivative related to Term Loan with related party	(108)	(770)
Change in fair value of warrant liabilities	28	(1,304)
Other, net	325	(682)
Total other income (expense)	(934)	(4,278)
Net loss	$ (13,534)	$ (17,965)
Net loss per share - basic	$ (2.66)	$ (131.77)
Net loss per share - diluted	$ (2.66)	$ (131.77)
Weighted-average number of common shares used in computing net loss per share - basic	5,094,809	136,333
Weighted-average number of common shares used in computing net loss per share - diluted	5,094,809	136,333
Other comprehensive loss:
Net loss	$ (13,534)	$ (17,965)
Comprehensive loss	(13,534)	(17,965)
Product [Member]
Revenue:
Total revenue	2,061	1,655
Costs and expenses:
Cost of product revenue	$ 4,202	3,995
Contribution [Member]
Revenue:
Total revenue		$ 423

TTOO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,208	$ 15,689
Accounts receivable, net	1,588	1,420
Inventories	4,670	4,819
Prepaid expenses and other current assets	3,094	3,261
Total current assets	15,560	25,189
Property and equipment, net	1,611	1,658
Operating lease right-of-use assets	7,031	7,395
Restricted cash	551	551
Other assets	2	4
Total assets	24,755	34,797
Current liabilities:
Accounts payable	1,887	1,527
Accrued expenses and other current liabilities	4,231	4,905
Operating lease liability	1,651	1,616
Warrant liabilities	207	235
Deferred revenue	185	224
Total current liabilities	56,256	56,152
Operating lease liabilities, net of current portion	6,180	6,598
Deferred revenue, net of current portion	92	83
Total liabilities	62,528	62,833
Commitments and contingencies (see Note 14)
Stockholders’ deficit
Preferred stock, $0.001 par value; 10,000,000 shares authorized: Series B Convertible Preferred Stock, 10,875 shares designated on March 31, 2024,10,875 and 93,297 shares issued and outstanding to related party on March 31, 2024 and December 31, 2023, respectively
Common stock, $0.001 par value; 400,000,000 shares authorized; 5,512,332 and 4,058,381 shares issued and outstanding on March 31,2024 and December 31, 2023, respectively	6	4
Additional paid-in capital	560,051	556,256
Accumulated deficit	(597,830)	(584,296)
Total stockholders’ deficit	(37,773)	(28,036)
Total liabilities and stockholders' deficit	24,755	34,797
Related Party [Member]
Current liabilities:
Notes payable	41,666	41,284
Accrued final payment fee on Term Loan	4,767	4,807
Derivative liability related to Term Loan	$ 1,662	$ 1,554

About T2 Biosystems Inc

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

CEO	Mr. John J. Sperzel III, B.Sc.
WEBSITE	t2biosystems.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	158

T2 Biosystems Inc Frequently Asked Questions

What is the ticker symbol for T2 Biosystems Inc? What does TTOO stand for in stocks?

TTOO is the stock ticker symbol of T2 Biosystems Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of T2 Biosystems Inc (TTOO)?

As of Fri May 17 2024, market cap of T2 Biosystems Inc is 49.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TTOO stock?

You can check TTOO's fair value in chart for subscribers.

What is the fair value of TTOO stock?

You can check TTOO's fair value in chart for subscribers. The fair value of T2 Biosystems Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of T2 Biosystems Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TTOO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is T2 Biosystems Inc a good stock to buy?

The fair value guage provides a quick view whether TTOO is over valued or under valued. Whether T2 Biosystems Inc is cheap or expensive depends on the assumptions which impact T2 Biosystems Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TTOO.

What is T2 Biosystems Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TTOO's PE ratio (Price to Earnings) is -1.09 and Price to Sales (PS) ratio is 6.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TTOO PE ratio will change depending on the future growth rate expectations of investors.